EUVIMEDEUVIMED entdecken
Crossref

The Laboratory Monitoring of Altuvoct (Efanesoctocog Alfa): Recommendations From the Laboratory Working Party of the United Kingdom Haemophilia Centres Doctor's Organisation

Annette Elizabeth Bowyer, Mohammed Khan, Caroline Lawrence, Stephen Macdonald, Jill Martin, Sean Platton, Anne Riddell, Jannene Sanders, Anna Williams iD, Stella Williams, Andrew Page

Haemophilia · 2026-01 · 32 (1) · 279-283

DOI: 10.1111/hae.70152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 07.11.2025. Verfasst von Annette Elizabeth Bowyer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Coagulation, Sheffield Teaching Hospitals NHSFT, Sheffield, UK. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

General Recommendations As assays tailored to Altuvoct are necessary, it is essential that every request for a FVIII level for monitoring of Altuvoct clearly identifies when it has been used for treatment of the patient and details the time of sampling relative to timing infusion. Recommendations For the Measurement of Altuvoct One‐stage assay APTT reagents that are suitable for the post‐infusion measurement of Altuvoct are Actin FSL, Synthafax and CK Prest following local verification or validation and when calibrated against a plasma standard (1B). Other one‐stage assay APTT reagents that may be suitable for the post‐infusion measurement of Altuvoct are APTT‐HS, APTT‐S, Pathromtin SL and Revohem, but more data with local validation are required (2B). APTT reagents that underestimate the post‐infusion measurement of Altuvoct are Synthasil and Thrombocheck SLA. These are not suitable for use (1B). APTT reagents that overestimate the post‐infusion measurement of Altuvoct are Actin, Actin FS, Cephen and Cephascreen. These are not suitable for use (1B). CSA are not suitable for the measurement of Altuvoct when calibrated against a plasma calibrator (1B). The use of a correction factor to approximate Altuvoct FVIII activity is not recommended (1B). Recommendations For the Monitoring of Altuvoct in the Presence of FVIII Mimetics In the presence of FVIII mimetic therapies, Altuvoct activity should be measured using a chromogenic FVIII assay that uses bovine FX and FIXa substrates (1B). In the presence of FVIII mimetic therapies, one‐stage FVIII assays should not be used; Altuvoct activity (measured using a chromogenic FVIII assay that uses bovine FX and FIXa substrates) must be reported with a caveat stating that this is an overestimation of Altuvoct in the order of 1.5–3.0‐fold (1B). Chromogenic FVIII assays that use human FX and FIXa substrates should not be used to measure Altuvoct activity in the presence of FVIII mimetics (1B). Chromogenic FVIII assays that use bovine FX and human FIXa substrates require local validation before they can be considered for measuring Altuvoct activity (or residual FVIII in a Bethesda or Nijmegen‐modified Bethesda assay) in the presence of FVIII mimetics (1C). Recommendations For the Monitoring of FVIII Inhibitors In the absence of FVIII mimetic therapy, FVIII inhibitors must be assessed using heat‐treated patient plasma and a one‐stage APTT assay to measure residual FVIII in a Bethesda or Nijmegen‐modified Bethesda assay (1B). In the presence of concomitant FVIII‐mimetic therapy, FVIII inhibitors must be assessed using heat‐treated patient plasma and a chromogenic FVIII assay that uses bovine FX and FIXa substrates to measure residual FVIII in a Bethesda or Nijmegen‐modified Bethesda assay (1B).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIHemophilia AHumansUnited KingdomRecombinant ProteinsBlood Coagulation TestsPartial Thromboplastin Time

Stichwörter der Autor:innen

AltuviiioAltuvoctFVIIIefanesoctocoghaemophilialaboratoryultra‐long

Substanzen

Factor VIIIRecombinant Proteins

Autor:innen und Institutionen

  • Department of Coagulation, Sheffield Teaching Hospitals NHSFT, Sheffield, UK.
  • Haematology Department, Aberdeen Royal Infirmary, Aberdeen, UK.
  • Department of Haemostasis, Glasgow Royal Infirmary, Glasgow, UK.
  • Specialist Haemostasis, Cambridge University Hospitals NHSFT, Cambridge, UK.
  • Royal London Hospital, London, UK.
  • Katharine Dormandy Haemophilia & Thrombosis Centre, Royal Free Hospital, Health Services Laboratories, London, UK.

ORCID-Profile: Anna Williams

Zitieren

APA

Bowyer, A. E., Khan, M., Lawrence, C., Macdonald, S., Martin, J., Platton, S., Riddell, A., Sanders, J., Williams, A., Williams, S., & Page, A. (2026). The Laboratory Monitoring of Altuvoct (Efanesoctocog Alfa): Recommendations From the Laboratory Working Party of the United Kingdom Haemophilia Centres Doctor's Organisation. Haemophilia, 32(1), 279-283. https://doi.org/10.1111/hae.70152

Vancouver

Bowyer AE, Khan M, Lawrence C, Macdonald S, Martin J, Platton S, et al. The Laboratory Monitoring of Altuvoct (Efanesoctocog Alfa): Recommendations From the Laboratory Working Party of the United Kingdom Haemophilia Centres Doctor's Organisation. Haemophilia. 2026;32(1):279-283. doi:10.1111/hae.70152

BibTeX
@article{Bowyer2026,
  author = {Bowyer, Annette Elizabeth and Khan, Mohammed and Lawrence, Caroline and Macdonald, Stephen and Martin, Jill and Platton, Sean and Riddell, Anne and Sanders, Jannene and Williams, Anna and Williams, Stella and Page, Andrew},
  title = {The Laboratory Monitoring of Altuvoct (Efanesoctocog Alfa): Recommendations From the Laboratory Working Party of the United Kingdom Haemophilia Centres Doctor's Organisation},
  journal = {Haemophilia},
  year = {2026},
  volume = {32},
  number = {1},
  pages = {279--283},
  doi = {10.1111/hae.70152}
}
Kostenlos starten →